Wells Fargo Raises Johnson & Johnson (JNJ) Price Target to $287
Wells Fargo has reaffirmed its Overweight rating on Johnson & Johnson, increasing the price target to $287, a 12.30% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Wells Fargo raised its price target on Johnson & Johnson ($JNJ) to $287 from $275 on October 16, 2026, and rates the stock "Overweight".
JNJ
Johnson & Johnson
Key Points
- On October 16, 2026, Wells Fargo maintained its Overweight rating on Johnson & Johnson, raising the price target from $275 to $287.
- Wells Fargo's $287 price target implies 12.30% upside from Johnson & Johnson's ($JNJ) current $255.56 share price.
- Johnson & Johnson's stock recently traded at $255.26, which is below the updated analyst target and 9.2% below its 52-week high.
- The average price target among analysts for Johnson & Johnson is $279.41, with 22 analysts offering their opinions.
Get $JNJ trade alerts by text
We text you when insiders, Congress or big funds trade $JNJ. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Johnson & Johnson alert may contain errors. Disclosures
Wells Fargo has reiterated its Overweight rating on Johnson & Johnson (NYSE: JNJ) and increased its price target from $275 to $287 on October 16, 2026. This comes as the stock trades recently around $255.26.
Wells Fargo vs. the S&P 500
Hypothetical returns from Wells Fargo's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Johnson & Johnson
Several other institutional investors have shown interest in Johnson & Johnson. BlackRock Inc. reduced its holdings by 1,280,271 shares, ending with 212,098,264 shares worth about $54.2 billion. Vanguard Capital Management LLC added 626,400 shares, bringing its total to 157,226,374 shares valued at approximately $40.2 billion. State Street Corporation increased its holdings by 293,661 shares, totaling 133,776,025 shares worth around $34.2 billion. Vanguard Portfolio Management LLC raised its stake by 857,431 shares, ending with 64,370,816 shares valued at about $16.5 billion. Geode Capital Management, LLC trimmed its position by 76,912 shares, leaving it with 59,086,417 shares worth about $15.1 billion.
Johnson & Johnson Stock Up 0.6%
As of October 16, 2026, Johnson & Johnson shares were trading at $255.26, which is about 3.8% below its 50-day moving average of $265.26. The stock is also 9.2% below its 52-week high of $281.07, but it remains 38.2% above its 52-week low of $184.66.
$JNJ price target
Johnson & Johnson daily closes and this analyst's $287 target. Not advice.
Recent Earnings
Johnson & Johnson reported trailing twelve-month revenue of approximately $99.3 billion, with a net margin of 16.2%. The next earnings report is scheduled for January 26, 2027.
Insider Buying and Selling at Johnson & Johnson
Recent insider transactions include Elizabeth Forminard, an Officer, who sold 15,918 shares on August 6, 2026, and Joaquin Boix Duato, the Chief Executive Officer, who sold 123,291 shares on August 13, 2026. Jennifer L. Taubert, another Officer, sold 15,000 shares at an average price of $263.36 on August 17, 2026. Timothy Schmid, also an Officer, sold 33,597 shares at an average price of $274.74 on September 2, 2026.
Analysts Set New Price Targets
On October 14, 2026, several firms maintained their ratings on Johnson & Johnson. Leerink Partners kept its Outperform rating with a target of $272.00, while RBC Capital maintained an Outperform rating with a target of $280.00. Morgan Stanley also maintained its Overweight rating with a target of $292.00. The consensus among analysts gives Johnson & Johnson a buy rating with a mean price target of approximately $279.41.
About Johnson & Johnson
Johnson & Johnson, headquartered in New Brunswick, NJ, is a leading healthcare company that develops and sells a variety of products across the healthcare field. The company operates in two main segments: Innovative Medicine and MedTech, making it a key player in the drug manufacturing industry.
Bottom Line
Wells Fargo's updated price target for Johnson & Johnson signals confidence in the company's future performance. Investors will be watching for the next earnings report on January 26, 2027, and any further analyst updates that may follow.
Related Filing Alerts
Source: Wells Fargo's rating change on $JNJ (Oct 16, 2026). Written by software, not financial advice. How we make alerts